Actuate Therapeutics Inc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACTU research report →
Range $21 – $21
Price Chart
About the company
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma.
- CEO
- Daniel Schmitt
- IPO
- 2024
- Employees
- 12
- HQ
- Fort Worth, TX, US
Get TickerSpark's AI analysis on ACTU
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $29.43M
- P/E
- -1.38
- PEG
- -0.02
- P/S
- 0.00
- P/B
- 29.68
- EV/EBITDA
- -1.24
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -346.18%
- ROIC
- -1489.99%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-22,495,312
- Net Income
- $-22,227,852+18.5%
- EPS
- $-1.06+67.5%
- OCF Growth
- +12.1%
- FCF Growth
- +12.1%
- 52W High
- $9.22
- 52W Low
- $0.90
- 50D MA
- $1.45
- 200D MA
- $3.60
- Beta
- 0.78
- RSI (14)
- 52
- Avg Volume
- 267.97K
No earnings-call transcripts are available for ACTU yet.
- Free Float
- 35.8%
- Shares Outstanding
- 23.93M
- Float Shares
- 8.57M
of shares held by institutions
44 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 529.11K | ▲ 213.10K |
| Cwm, LLC | 1.87K | ▲ 1.87K |
Held by 21 ETFs
Biggest fund positions in ACTU by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 14, 26 | SCHMITT DANIEL M | other | 272,056 |
| Aug 14, 26 | SCHMITT DANIEL M | other | 120,521 |
| Aug 14, 26 | SCHMITT DANIEL M | other | 272,056 |
| May 21, 26 | Zabrowski Dan | other | 15,000 |
| May 21, 26 | THOMSON TODD S | other | 15,000 |
| May 21, 26 | Sawhney Roger | other | 15,000 |
| May 21, 26 | RONNEBERG AMY L | other | 15,000 |
| May 21, 26 | Keyes Jason A | other | 15,000 |
| May 21, 26 | Huber Martin H. Jr. | other | 15,000 |
| May 21, 26 | Fletcher Aaron G.L. | other | 15,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ACTU coverage
Recent articles, reports, and earnings notes.
No research on ACTU yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ACTU report →Actuate Therapeutics' Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma
globenewswire.com · Jun 9
Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer
globenewswire.com · Jun 1
Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program
globenewswire.com · May 11
Analysts see 200%+ upside in these 3 high-risk stocks: here's why?
invezz.com · May 9
Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors
globenewswire.com · May 6
Actuate Therapeutics drug improves survival odds in pancreatic cancer trial
reuters.com · Apr 22
Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
globenewswire.com · Apr 14
Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers
accessnewswire.com · Mar 24
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.